SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Eugene V McCloskey, Nicholas C Harvey, John A Kanis, Can we treat to target in osteoporosis?, International Journal of Clinical Rheumatology, 2015, 10, 1, 1

    CrossRef

  2. 2
    Philippe Zysset, Ling Qin, Thomas Lang, Sundeep Khosla, William D. Leslie, John A. Shepherd, John T. Schousboe, Klaus Engelke, Clinical Use of Quantitative Computed Tomography–Based Finite Element Analysis of the Hip and Spine in the Management of Osteoporosis in Adults: the 2015 ISCD Official Positions—Part II, Journal of Clinical Densitometry, 2015, 18, 3, 359

    CrossRef

  3. 3
    Philippe Zysset, Dieter Pahr, Klaus Engelke, Harry K. Genant, Michael R. McClung, David L. Kendler, Christopher Recknor, Michael Kinzl, Jakob Schwiedrzik, Oleg Museyko, Andrea Wang, Cesar Libanati, Comparison of proximal femur and vertebral body strength improvements in the FREEDOM trial using an alternative finite element methodology, Bone, 2015, 81, 122

    CrossRef

  4. 4
    Kenneth ES Poole, Graham M Treece, Andrew H Gee, Jacques P Brown, Michael R McClung, Andrea Wang, Cesar Libanati, Denosumab Rapidly Increases Cortical Bone in Key Locations of the Femur: A 3D Bone Mapping Study in Women With Osteoporosis, Journal of Bone and Mineral Research, 2015, 30, 1
  5. 5
    Christian Muschitz, Roland Kocijan, Dieter Pahr, Janina M. Patsch, Karin Amrein, Barbara M. Misof, Alexandra Kaider, Heinrich Resch, Peter Pietschmann, Ibandronate Increases Sclerostin Levels and Bone Strength in Male Patients with Idiopathic Osteoporosis, Calcified Tissue International, 2015, 96, 6, 477

    CrossRef

  6. 6
    Barbara M Misof, Nadja Fratzl-Zelman, Eleftherios P Paschalis, Paul Roschger, Klaus Klaushofer, Long-term safety of antiresorptive treatment: bone material, matrix and mineralization aspects, BoneKEy Reports, 2015, 4, 634

    CrossRef

  7. 7
    Vikram Khedgikar, Naseer Ahmad, Priyanka Kushwaha, Jyoti Gautam, Geet K. Nagar, Divya Singh, Prabodh K. Trivedi, Prabhat R. Mishra, Neelam S. Sangwan, Ritu Trivedi, Preventive effects of withaferin A isolated from the leaves of an Indian medicinal plant Withania somnifera (L.): Comparisons with 17-β-estradiol and alendronate, Nutrition, 2015, 31, 1, 205

    CrossRef

  8. 8
    S. Papapoulos, K. Lippuner, C. Roux, C. J. F. Lin, D. L. Kendler, E. M. Lewiecki, M. L. Brandi, E. Czerwiński, E. Franek, P. Lakatos, C. Mautalen, S. Minisola, J. Y. Reginster, S. Jensen, N. S. Daizadeh, A. Wang, M. Gavin, C. Libanati, R. B. Wagman, H. G. Bone, The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study, Osteoporosis International, 2015,

    CrossRef

  9. 9
    Yong-Ki Min, Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis, Endocrinology and Metabolism, 2015, 30, 1, 19

    CrossRef

  10. 10
    Denosumab enhances bone strength, so reducing fracture risk, IBMS BoneKEy, 2014, 11,

    CrossRef

  11. 11
    J. P. Brown, C. Roux, P. R. Ho, M. A. Bolognese, J. Hall, H. G. Bone, S. Bonnick, J. P. van den Bergh, I. Ferreira, P. Dakin, R. B. Wagman, C. Recknor, Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate, Osteoporosis International, 2014,

    CrossRef

  12. 12
    Lesley J. Scott, Denosumab: A Review of its Use in Postmenopausal Women with Osteoporosis, Drugs & Aging, 2014, 31, 7, 555

    CrossRef